Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911626 | 0.90 | GRM2 (0.55) | SMN1; SMN2MAPTPLA2G1BCYP1A2CYP3A4 | |
| SCHEMBL3092869 | 0.87 | HSD17B10 (0.51) | SMN1; SMN2MAPTHSD17B10MAPK1GRM2 | |
| SCHEMBL1909166 | 0.87 | GRM2 (0.53) | CYP1A2CYP3A4KMT2AHSD17B10MAPK1 | |
| SCHEMBL28595790 | 0.86 | ESR1 (0.55) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2821953 | 0.86 | LMNA (0.54) | SMN1; SMN2MAPTHSD17B10GRM2LMNA | |
| SCHEMBL554548 | 0.85 | GRM2 (0.51) | SMN1; SMN2CYP1A2CYP3A4KMT2AHSD17B10 | |
| SCHEMBL16246754 | 0.85 | KLKB1 (0.57) | HSD17B10GRM2LMNAALDH1A1KLKB1 | |
| SCHEMBL553801 | 0.85 | GRM2 (0.53) | CYP1A2CYP3A4HSD17B10GRM2LMNA | |
| SCHEMBL30739426 | 0.84 | GRM2 (0.50) | CYP1A2CYP3A4HSD17B10GRM2LMNA | |
| SCHEMBL3093449 | 0.84 | GRM2 (0.63) | SMN1; SMN2MAPTKMT2AMAPK1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048570-A1 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | Kainos Medicine, Inc (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| EP-2144895-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2118081-A2 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | Kainos Medicine, Inc., (KR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008087560-A2 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | KAINOS MEDICINE, INC., (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | SMN1; SMN2 618/4885MAPT 3377/4885PLA2G1B 1893/4885 |
| US-20100048570-A1 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | DPP4, DPP3, DPP7 | SMN1; SMN2 2955/4885MAPT 3670/4885PLA2G1B 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.